Deep knowledge on 
 small-molecule drugs and 
 the 110,000 global patents 
 covering them 

Free Patent Expiration Alerts


Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Zolmitriptan - Generic Drug Details

« Back to Dashboard
Zolmitriptan is the generic ingredient in three branded drugs marketed by Aurobindo Pharma Ltd, Astrazeneca, Alembic Pharms Ltd, Macleods Pharms Ltd, Ajanta Pharma Ltd, Jubilant Generics, Glenmark Generics, Teva Pharms Usa, IPR, Apotex Inc, Sun Pharma Global, Invagen Pharms, Mylan Pharms Inc, and Zydus Pharms Usa Inc, and is included in nineteen NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are twenty drug master file entries for zolmitriptan. Eighteen suppliers are listed for this compound.

Summary for Generic Name: zolmitriptan

Tradenames:3
Patents:2
Applicants:14
NDAs:19
Drug Master File Entries: see list20
Suppliers / Packaging: see list18
Therapeutic Class:Antimigraine Agents
Formulation / Manufacturing:see details

Clinical Trials for: zolmitriptan

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa
ZOLMITRIPTAN
zolmitriptan
TABLET;ORAL090861-001Mar 4, 2014RXNo<disabled><disabled>
Zydus Pharms Usa Inc
ZOLMITRIPTAN
zolmitriptan
TABLET, ORALLY DISINTEGRATING;ORAL202890-001May 15, 2013RXNo<disabled><disabled>
Astrazeneca
ZOMIG-ZMT
zolmitriptan
TABLET, ORALLY DISINTEGRATING;ORAL021231-002Sep 17, 2001RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: zolmitriptan

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ipr
ZOMIG
zolmitriptan
TABLET;ORAL020768-001Nov 25, 19975,863,935*PED<disabled>
Ipr
ZOMIG
zolmitriptan
TABLET;ORAL020768-002Nov 25, 19975,466,699*PED<disabled>
Astrazeneca
ZOMIG
zolmitriptan
SPRAY;NASAL021450-004Sep 30, 20035,466,699*PED<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Connect with Social Media:

`abc